drugset / Trial / NCT06768697
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
RandomizedSequentialQuadruple-blindPrevention
Summary
The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection. It will also learn about the Safety and immunogenicity of the vaccine.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KFD1 | Protein / enzyme biologic | 0 ug | Intranasal |
| Subject | KFD1 | Protein / enzyme biologic | 20 ug | Intranasal |
| Subject | KFD1 | Protein / enzyme biologic | 40 ug | Intranasal |
| Subject | KFD1 | Protein / enzyme biologic | 80 ug | Intranasal |